SBC Medical Group Holdings Incorporated (SBC)

SBC Medical Group Holdings, Inc. was listed on Nasdaq in September 2024 and included in the Russell 3000 Index in June 2025. In March 2026, the company announced its Q4 and full-year 2025 financial results, with Q4 EPS more than doubling but revenues decreasing. SBC Medical also announced its "SBC Wellness 2.0" strategy and the opening of its "NEO Skin Clinic Ginza." Chairman and CEO Yoshiyuki Aikawa sold 4,422,900 shares. While SBC has underperformed the broader market over the last year, it has shown stronger performance in the last three months and two-week periods.

Based on historical stock price data, November has the highest probability of positive returns for SBC, followed by March. While specific details on product and service demand seasonality were not explicitly found, the company's focus on aesthetic healthcare could imply some level of seasonality. The launch of "SBC Wellness 2.0" and its B2B model could also introduce new demand patterns.

SBC Medical Group Holdings, Inc. (SBC) is a Management Services Organization (MSO) providing management support to franchise businesses in medical fields such as aesthetics, dermatology, orthopedics, fertility, gynecology, dentistry, alopecia treatment, and ophthalmology. SBC offers services like advertising, staff management, reservations, facility assistance, equipment procurement, technology licensing, IT solutions, and customer rewards programs. The company also owns and operates treatment centers under the SBC brand.

SBC Medical Group Holdings, Inc. has headquarters in Irvine, California, USA, and Tokyo, Japan, and is expanding internationally, particularly in the United States and Asia. As of December 31, 2025, it supported 237 franchisee treatment centers in Japan and directly operated 21 centers in Singapore and one in Vietnam. The company also holds an approximately 18.2% voting interest in OT Midco, which operates 24 OrangeTwist locations across six U.S. states.

SBC Medical Group Holdings aims to be the top aesthetic medical provider in Japan by customer volume and is focused on strengthening its international reputation for quality and trust in medical care. The company's "SBC Wellness 2.0" strategy positions it to pioneer the "Performance Medicine" category. The opening of a brand flagship "NEO Skin Clinic Ginza" also contributes to brand visibility. The company had 6.6 million customers in the last twelve months, with a 72% repeat customer rate. However, the company has disclosed material weaknesses in internal control over financial reporting and a warning that Nasdaq may delist its securities, which could negatively impact its reputation.

As of March 30, 2026, 60.82% of SBC Medical Group's stock is owned by institutional investors, including Geode Capital Management LLC, Millennium Management LLC, and BlackRock, Inc. Yoshiyuki Aikawa, the Chairman and CEO, beneficially owns approximately 85.2% of the company's outstanding shares as of December 26, 2025, maintaining controlling interest.